Prostatype Genomics Dirección

Dirección controles de criterios 1/4

El CEO de Prostatype Genomics' es Fredrik Persson, nombrado en Jan 2017, tiene una permanencia de 7.25 años. posee directamente un 0.025% de las acciones de la empresa, con un valor de SEK9.18K. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 5.3 años, respectivamente.

Información clave

Fredrik Persson

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	7.3yrs
Participación del CEO	0.03%
Permanencia media de la dirección	1.4yrs
Promedio de permanencia en la Junta Directiva	5.3yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Fredrik Persson

7.3yrs

Permanencia

Mr. Fredrik Persson has been Chief Executive Officer of Prostatype Genomics AB (publ) since 2017 and serves as its Managing Director. He has years of international life science industry experience in lead...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Fredrik Persson	CEO & MD	7.3yrs	sin datos	0.025% SEK 7.7k
Anders Koch	Chief Financial Officer	less than a year	sin datos	sin datos
George Skinner	Vice President Commercial operations	no data	sin datos	sin datos
Emelie Berglund	Chief Technology Officer	1.5yrs	sin datos	0.0012% SEK 356.3
Nicklas Rosendal	Communications Director	2.7yrs	sin datos	sin datos
Joakim Soderin	Chief Auditor	1.9yrs	sin datos	sin datos
Gerald Andriole	Global Chief Medical Officer	less than a year	sin datos	sin datos
Steven Gaal	President of Prostatype Genomics Inc.	1.3yrs	sin datos	sin datos
Katarina Sjöberg	QA & RA Manager	1.3yrs	sin datos	sin datos
Mats Bergström	Sales Director of EMEA	no data	sin datos	sin datos

1.4yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de PROGEN no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Anders Lundberg	Independent Chairman of the Board	7.3yrs	sin datos	sin datos
Mattias Prage	Independent Director	1.9yrs	sin datos	sin datos
Hakan Englund	Independent Director	5.3yrs	sin datos	0.071% SEK 21.9k
Michael Haggman	Independent Director	6.3yrs	sin datos	0.0015% SEK 460.7
Rolf Skoglund	Member of Advisory Board	no data	sin datos	sin datos
Jörgen Dahlström	Independent Director	less than a year	sin datos	sin datos

5.3yrs

Permanencia media

Junta con experiencia: La junta directiva de PROGEN se considera experimentada (5.3 años de antigüedad promedio).

Prostatype Genomics Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Prostatype Genomics AB (publ) Announces Henrik Nilsson to Leave the Board of Directors Prematurely

Prostatype Genomics Appoints Anders Koch as New CFO

Prostatype Genomics CFO Michael af Winklerfelt Leaving the Company

Prostatype Genomics AB Appoints Gerald Andriole as Chief Medical Officer

Prostatype Genomics AB (Publ) Announces Executive Changes

Prostatype Genomics AB Appoints Professor Gerald Andriole as Chief Medical Officer

Recent updates

Prostatype Genomics Announces Very Strong Interim Results from Long-Term Follow-Up Study with Prostatype in Uppsala

Prostatype Genomics Updates on Significant Progress in the US Study with Prostatype®

Prostatype Genomics AB (publ) to Report Fiscal Year 2024 Results on Feb 13, 2025

Full year 2023 earnings released

New major risk - Revenue and earnings growth

Prostatype Genomics AB (publ) Announces Long Term Follow Up Study At Akademiska University Hospital, Uppsala, to Be Presented At EAU-Meeting, May 2024: Indicates New Area of Use for Prostatype®

Prostatype Genomics AB (publ) Announces Henrik Nilsson to Leave the Board of Directors Prematurely

Prostatype Genomics Appoints Anders Koch as New CFO

Prostatype Genomics AB (Publ) Announces Updated Strategy and Implementation of Efficiency Programs in Prostatype Genomics

Prostatype Genomics Announces New Multi-Centre Study in Spain Shows Very Strong Interim Results for Prostatype(R)

New major risk - Share price stability

Prostatype Genomics CFO Michael af Winklerfelt Leaving the Company

Second quarter 2023 earnings: Revenues miss analyst expectations

Prostatype Genomics AB (Publ) Provides Revenue Guidance for the Third Quarter of 2023

Now 26% undervalued after recent price drop

Prostatype Genomics AB Appoints Gerald Andriole as Chief Medical Officer

First quarter 2023 earnings released

Prostatype Genomics AB (Publ) Announces Executive Changes

Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 17.787846 million.

Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 17.787846 million.

Prostatype Genomics AB Appoints Professor Gerald Andriole as Chief Medical Officer

Full year 2022 earnings released: kr1.27 loss per share (vs kr1.11 loss in FY 2021)

Prostatype Genomics AB (publ) to Report Fiscal Year 2022 Results on May 04, 2023

Prostatype Genomics AB (publ) to Report Q2, 2023 Results on Aug 17, 2023

Prostatype Genomics Appoints Steven Gaal as President

Prostatype Genomics AB (Publ) Provides Sales Guidance for the Year 2022

Prostatype Genomics Announces Management Changes

Prostatype Shows Strong Data in Asian Pilot Study

Second quarter 2022 earnings released

High number of new directors

Prostatype Genomics AB (Publ) Appoints Mattias Prage as Member of the Board

First quarter 2022 earnings released

Insufficient new directors

Prostatype Genomics AB (publ) to Report Q3, 2022 Results on Nov 10, 2022

Insufficient new directors

CEO & MD recently bought kr72k worth of stock

Insider recently bought kr108k worth of stock

Third quarter 2021 earnings released

Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 24.724583 million.

Second quarter 2021 earnings released: kr0.18 loss per share (vs kr0.42 loss in 2Q 2020)

Prostatype Genomics AB (publ) to Report Q4, 2020 Results on May 17, 2021

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media